Health Care & Life Sciences » Pharmaceuticals | Clearside Biomedical Inc.

Clearside Biomedical Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
520.00
345.00
30
Cost of Goods Sold (COGS) incl. D&A
15.00
33.00
60.00
-
-
-
Gross Income
15.00
33.00
60.00
-
-
-
SG&A Expense
7,223.00
9,790.00
17,257.00
25,653.00
58,571.00
82,786
EBIT
7,238.00
9,823.00
17,317.00
25,198.00
58,408.00
82,945
Non Operating Income/Expense
-
-
-
684.00
567.00
1,184
Interest Expense
23.00
371.00
330.00
-
-
1,057
Pretax Income
7,254.00
10,189.00
17,639.00
25,882.00
58,975.00
82,818
Consolidated Net Income
7,254.00
10,189.00
17,639.00
25,882.00
58,975.00
82,818
Net Income
7,254.00
10,189.00
17,639.00
25,882.00
58,975.00
82,818
Net Income After Extraordinaries
7,254.00
10,189.00
17,639.00
25,882.00
58,975.00
82,818
Net Income Available to Common
7,254.00
10,189.00
17,639.00
25,882.00
58,975.00
82,818
EPS (Basic)
0.35
0.49
0.85
1.97
2.33
2.69
Basic Shares Outstanding
20,672.70
20,672.70
20,672.70
13,111.10
25,311.60
30,733.60
EPS (Diluted)
0.35
0.49
0.85
1.97
2.33
2.69
Diluted Shares Outstanding
20,672.70
20,672.70
20,672.70
13,111.10
25,311.60
30,733.60
EBITDA
7,223.00
9,790.00
17,257.00
25,133.00
58,226.00
82,756
Non-Operating Interest Income
7.00
5.00
8.00
-
-
-

About Clearside Biomedical

View Profile
Address
900 North Point parkway
Alpharetta Georgia 30005
United States
Employees -
Website http://www.clearsidebio.com
Updated 07/08/2019
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.